Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

TIMOTHY J CRAIG

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1609825306
CMS profile
117800
Location
HERSHEY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$148,499.67

157 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

TIMOTHY J CRAIG

NPI 1609825306 · CMS profile ID 117800

Allopathic & Osteopathic Physicians / Allergy & Immunology

HERSHEY, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609825306?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
TIMOTHY J CRAIG, NPI 1609825306, CMS profile ID 117800. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609825306?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). TIMOTHY J CRAIG, NPI 1609825306, CMS profile ID 117800. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609825306?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
TIMOTHY J CRAIG, NPI 1609825306, CMS profile ID 117800, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1609825306?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

157 matching records · $148,499.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 157 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 157.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
CSL Behring $597.9404/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004231 CMS
CSL Behring $591.8604/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004243 CMS
CSL Behring $481.1304/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004253 CMS
CSL Behring $589.7804/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004265 CMS
CSL Behring $452.1404/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004273 CMS
Pharming Healthcare, Inc. $87.5004/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1029328329 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,145.0004/13/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372959 CMS
CSL Behring $4,128.3004/05/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004401 CMS
CSL Behring $150.1604/05/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004411 CMS
Grifols USA, LLC $66.9104/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809701 CMS
CSL Behring $6,600.0004/03/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043005017 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,604.1604/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372957 CMS
CSL Behring $1,625.0003/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004223 CMS
CSL Behring $228.1203/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004125 CMS
CSL Behring $273.6703/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004135 CMS
CSL Behring $626.0503/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004147 CMS
CSL Behring $271.6503/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004159 CMS
CSL Behring $776.9403/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004169 CMS
CSL Behring $120.6803/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004179 CMS
CSL Behring $304.0003/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004187 CMS
CSL Behring $366.9003/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004199 CMS
CSL Behring $528.3103/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004211 CMS
BioCryst Pharmaceuticals, Inc. $1,925.0003/15/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560063 CMS
BioCryst Pharmaceuticals, Inc. $146.5803/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560079 CMS
Takeda Pharmaceuticals U.S.A., Inc. $184.3603/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372943 CMS
Takeda Pharmaceuticals U.S.A., Inc. $49.7703/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372945 CMS
Takeda Pharmaceuticals U.S.A., Inc. $43.8903/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372947 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.8403/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372949 CMS
Takeda Pharmaceuticals U.S.A., Inc. $26.9103/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372951 CMS
Takeda Pharmaceuticals U.S.A., Inc. $75.0003/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372953 CMS
Takeda Pharmaceuticals U.S.A., Inc. $32.2903/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372955 CMS
Takeda Pharmaceuticals U.S.A., Inc. $119.8503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372939 CMS
Takeda Pharmaceuticals U.S.A., Inc. $48.3303/09/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372941 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6,906.2303/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055372937 CMS
Blueprint Medicines Corporation $64.2602/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051267293 CMS
CSL Behring $258.7702/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004093 CMS
CSL Behring $226.4202/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004103 CMS
CSL Behring $181.1402/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004115 CMS
Novartis Pharmaceuticals Corporation $41.9702/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991598697 CMS
BioCryst Pharmaceuticals, Inc. $202.6002/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012560071 CMS
CSL Behring $281.4102/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004085 CMS
CSL Behring $73.8402/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004391 CMS
Grifols USA, LLC $8.0002/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809706 CMS
Grifols USA, LLC $61.9502/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809713 CMS
Grifols USA, LLC $2,665.0002/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809719 CMS
Grifols USA, LLC $180.7802/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809725 CMS
Grifols USA, LLC $239.5702/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809731 CMS
Grifols USA, LLC $61.0002/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809737 CMS
Grifols USA, LLC $61.9502/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011809739 CMS
CSL Behring $1,980.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1043004677 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $53,280.97 80
PY2020 $52,068.95 50
PY2021 $76,151.89 53
PY2022 $47,513.25 60
PY2023 $148,499.67 157
PY2024 $86,500.42 120
PY2025 $100,003.97 119

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $194,213.36 76
PY2024 Principal investigator $227,338.87 86
PY2023 Principal investigator $79,455.08 48
PY2022 Principal investigator $233,218.35 88
PY2021 Principal investigator $228,959.35 49
PY2020 Principal investigator $179,085.08 34
PY2019 Principal investigator $293,793.25 84

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

76 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,050.00 12/30/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246792049
Principal investigator 1 Ionis Pharmaceuticals, Inc. $18,320.62 12/10/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246791344
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,308.69 12/10/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $294.75 12/10/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 12/10/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266769
Principal investigator 1 CSL Behring $1,000.00 12/05/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671624
Principal investigator 1 CSL Behring $1,000.00 11/20/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671616
Principal investigator 1 CSL Behring $2,849.00 11/20/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671618
Principal investigator 1 CSL Behring $3,500.00 11/20/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671620
Principal investigator 1 CSL Behring $7,499.00 11/20/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671622
Principal investigator 1 CSL Behring $2,849.00 11/20/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671626
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 11/10/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246790246
Principal investigator 1 Ionis Pharmaceuticals, Inc. $750.00 11/10/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246790250
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,589.43 11/03/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266761
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,300.00 10/29/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246789797
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,202.00 10/23/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246789558
Principal investigator 1 Ionis Pharmaceuticals, Inc. $100.00 10/23/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246789561
Principal investigator 1 CSL Behring $946.00 10/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671614
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 10/22/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223266759
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 10/17/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266753
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,500.00 10/17/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 10/17/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266757
Principal investigator 1 Ionis Pharmaceuticals, Inc. $600.00 10/10/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
IS744CS3 No dispute reported 06/30/2026 1246788737
Principal investigator 1 GlaxoSmithKline, LLC. $1,123.70 10/02/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168094
Principal investigator 1 CSL Behring $108.51 09/30/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671650
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 09/19/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266751
Principal investigator 1 CSL Behring $171.80 09/09/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671672
Principal investigator 1 CSL Behring $85.90 09/09/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671674
Principal investigator 1 CSL Behring $19.34 09/09/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671676
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,432.07 09/02/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266749
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 08/28/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
IS744CS3 No dispute reported 06/30/2026 1246786870
Principal investigator 1 GlaxoSmithKline, LLC. $1,150.00 08/20/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168079
Principal investigator 1 CSL Behring $4,687.00 08/18/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671602
Principal investigator 1 GlaxoSmithKline, LLC. $1,880.00 08/07/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168090
Principal investigator 1 GlaxoSmithKline, LLC. $1,888.00 08/07/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168099
Principal investigator 1 Ionis Pharmaceuticals, Inc. $20,094.54 08/07/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246786335
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,562.00 08/01/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223266743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 08/01/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223266745
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 08/01/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis No dispute reported 06/30/2026 1223266747
Principal investigator 1 CSL Behring $1,200.00 07/18/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671598
Principal investigator 1 CSL Behring $2,107.00 07/14/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671596
Principal investigator 1 CSL Behring $4,217.00 07/09/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671594
Principal investigator 1 Ionis Pharmaceuticals, Inc. $500.00 07/03/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
IS744CS3 No dispute reported 06/30/2026 1246785008
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 07/03/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
IS744CS3 No dispute reported 06/30/2026 1246785012
Principal investigator 1 Ionis Pharmaceuticals, Inc. $8,312.63 07/03/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
IS744CS3 No dispute reported 06/30/2026 1246785015
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,100.00 06/23/2025 Non-covered Recipient Entity
THE PENNSYLVANIA UNIVERSITYCOLLEGE OF MEDICINE
IS744CS7 No dispute reported 06/30/2026 1246784476
Principal investigator 1 CSL Behring $2,107.00 06/09/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671588
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 06/06/2025 Non-covered Recipient Entity
PENNSYLVANIA STATE UNIVERSITY
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280904
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,251.06 06/04/2025 Non-covered Recipient Entity
PENNSYLVANIA STATE UNIVERSITY
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280694
Principal investigator 1 CSL Behring $1,892.00 05/30/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671586
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,150.00 05/28/2025 Non-covered Recipient Entity
PENNSYLVANIA STATE UNIVERSITY
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280436
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 05/23/2025 Non-covered Recipient Entity
PENNSYLVANIA STATE UNIVERSITY
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223280250
Principal investigator 1 CSL Behring $300.00 05/21/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671582
Principal investigator 1 CSL Behring $600.00 05/21/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671584
Principal investigator 1 CSL Behring $235.00 05/14/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671578
Principal investigator 1 CSL Behring $4,316.00 05/14/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671580
Principal investigator 1 CSL Behring $800.00 05/12/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671574
Principal investigator 1 CSL Behring $1,500.00 05/12/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671576
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 05/09/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192164967
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 05/09/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192168087
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 05/02/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192168083
Principal investigator 1 CSL Behring $176.72 04/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671520
Principal investigator 1 CSL Behring $639.00 04/16/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671572
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 04/16/2025 Non-covered Recipient Entity
THE PENNSYLVANIA STATE UNIVERSITY
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192164963
Principal investigator 1 CSL Behring $226.72 04/14/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671518
Principal investigator 1 CSL Behring $2,424.00 04/11/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671570
Principal investigator 1 CSL Behring $4,340.00 03/14/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671568
Principal investigator 1 CSL Behring $6,996.00 03/12/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671566
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,054.93 02/12/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266717
Principal investigator 1 CSL Behring $400.00 01/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671702
Principal investigator 1 CSL Behring $750.00 01/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671704
Principal investigator 1 CSL Behring $1,000.00 01/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671706
Principal investigator 1 CSL Behring $3,500.00 01/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671708
Principal investigator 1 CSL Behring $4,178.00 01/22/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
A Phase 3 Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema in Pediatric Subjects 2 to 11 Years of Age No dispute reported 06/30/2026 1252671710
Principal investigator 1 CSL Behring $2,170.00 01/17/2025 Non-covered Recipient Entity
Penn State State College Of Medicine
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema No dispute reported 06/30/2026 1252671700
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $58.95 01/15/2025 Covered Recipient Teaching Hospital
HOLY SPIRIT HOSPITAL
STUDY TO CHECK THE SAFETY OF FAZIRSIRAN AND LEARN IF FAZIRSIRAN CAN HELP PEOPLE WITH LIVER DISEASE AND SCARRING (FIBROSIS) DUE TO AN ABNORMAL VERSION OF ALPHA-1 ANTITRYPSIN PROTEIN No dispute reported 06/30/2026 1223266715